NasdaqGS:ABCLLife Sciences
AbCellera (ABCL) Valuation Check After Bruker Patent Settlement, New Royalty Stream and Legal Overhang Removal
AbCellera Biologics (ABCL) just took a legal overhang off the table by signing a global settlement and patent license deal with Bruker that brings in $36 million upfront plus future royalties.
See our latest analysis for AbCellera Biologics.
The legal clean up helps explain why the 1 day share price return jumped 5.37 percent, even as the 90 day share price return is still down 21.73 percent. With a 23.86 percent 1 year total shareholder return versus a deeply negative 3 year total...